Human microglia and astrocytes constitutively express the neurokinin-1 receptor and functionally respond to substance P

Amanda R. Burmeister 1, M. Brittany Johnson 1, Vinita S. Chauhan 1, Megan J. Moerdyk-Schauwecker 1, Ada D. Young 1, Ian D. Cooley 1, Alejandra N. Martinez 2, Geeta Ramesh 2, Mario T. Philipp 2 and Ian Marriott 1*

Abstract

Background: The tachykinin substance P (SP) is recognized to exacerbate inflammation at peripheral sites via its target receptor, neurokinin 1 receptor (NK-1R), expressed by leukocytes. More recently, SP/NK-1R interactions have been associated with severe neuroinflammation and neuronal damage. We have previously demonstrated that NK-1R antagonists can limit neuroinflammatory damage in a mouse model of bacterial meningitis. Furthermore, we have since shown that these agents can attenuate bacteria-induced neuronal and glial inflammatory mediator production in nonhuman primate (NHP) brain explants and isolated neuronal cells, and following in vivo infection.

Methods: In the present study, we have assessed the ability of NHP brain explants, primary human microglia and astrocytes, and immortalized human glial cell lines to express NK-1R isoforms. We have utilized RT-PCR, immunoblot analysis, immunofluorescent microscopy, and/or flow cytometric analysis, to quantify NK-1R expression in each, at rest, or following bacterial challenge. Furthermore, we have assessed the ability of human microglia to respond to SP by immunoblot analysis of NF-kB nuclear translocation and determined the ability of this neuropeptide to augment inflammatory cytokine release and neurotoxic mediator production by human astrocytes using an ELISA and a neuronal cell toxicity assay, respectively.

Results: We demonstrate that human microglial and astrocytic cells as well as NHP brain tissue constitutively express robust levels of the full-length NK-1R isoform. In addition, we demonstrate that the expression of NK-1R by human astrocytes can be further elevated following exposure to disparate bacterial pathogens or their components. Importantly, we have demonstrated that NK-1R is functional in both human microglia and astrocytes and show that SP can augment the inflammatory and/or neurotoxic immune responses of glial cells to disparate and clinically relevant bacterial pathogens.

Conclusions: The robust constitutive and functional expression of the full-length NK-1R isoform by human microglia and astrocytes, and the ability of SP to augment inflammatory signaling pathways and mediator production by these cells, support the contention that SP/NK-1R interactions play a significant role in the damaging neuroinflammation associated with conditions such as bacterial meningitis.

Keywords: Substance P, Neurokinin-1 receptor, Neuroinflammation, Human, Microglia, Astrocyte
Background

The neuropeptide substance P (SP) and its selective receptor, the neurokinin-1 receptor (NK-1R), is expressed at high levels within the central nervous system (CNS) (as reviewed in [1, 2]). In addition to its functions as a neurotransmitter in the perception of pain and its essential role in gut motility, this tachykinin is now recognized to exacerbate inflammation at peripheral sites including the skin, lung, and gastrointestinal and urogenital tracts. Indeed, this neuropeptide appears to contribute to disease pathology for some infectious agents. For example, SP increases the bronchoconstriction and damaging cardiac inflammation following infection with respiratory syncytial virus and encephalomyocarditis virus, respectively [3, 4]. Likewise, SP contributes to the severity of inflammation associated with Trypanosoma brucei brucei infection and inflammation and granuloma size in a mouse model of Taenia solium cysticercosis [5–7].

Recently, a number of studies have identified a similar role for SP and NK-1R interactions in neuroinflammation (as discussed in [1, 2]), and our data suggests that SP exacerbates damaging inflammation within the CNS in animal models in response to disparate bacterial pathogens. We determined that the absence of SP/NK-1R interactions in SP receptor-deficient mice or prophylactic pharmacological NK-1R inhibition in wild type animals significantly reduces bacteria-induced neuroinflammation and resultant CNS damage [8, 9]. NK-1R null mice and mice treated with an NK-1R antagonist showed reduced inflammatory and maintained immunosuppressive cytokine production, as well as decreased astrogliosis, cellularity, and demyelination following intracerebral administration of the Gram-negative bacterial pathogens Neisseria meningitidis and Borrelia burgdorferi, or the Gram-positive bacterium Streptococcus pneumoniae [8, 9]. More recently, we have demonstrated that the specific NK-1R antagonist, aprepitant, limits inflammatory and maintained immunosuppressive cytokine production, as well as decreased astrogliosis, cellularity, and demyelination following intracerebral administration of the Gram-negative bacterial pathogens Neisseria meningitidis and Borrelia burgdorferi, or the Gram-positive bacterium Streptococcus pneumoniae [8, 9]. More recently, we have demonstrated that the specific NK-1R antagonist, aprepitant, limits inflammatory and maintained immunosuppressive cytokine production, as well as decreased astrogliosis, cellularity, and demyelination following intracerebral administration of the Gram-negative bacterial pathogens Neisseria meningitidis and Borrelia burgdorferi, or the Gram-positive bacterium Streptococcus pneumoniae [8, 9].

Methods

Bacterial propagation

First passage B. burgdorferi strain B31 clone 5A19 spirochetes, isolated from an ear biopsy of a previously infected mouse, were grown in Barbour-Stoenner-Kelly-H medium supplemented with 6% rabbit serum and antibiotics (rifampicin at 45.4 μg/mL, phosphomycin at 193 μg/mL, and amphotericin at 0.25 μg/mL; Sigma-Aldrich, St. Louis, MO) to late logarithmic phase under microaerophilic conditions. An inoculum containing 1 × 10^7 spirochetes/mL in RPMI 1640 medium (Invitrogen, USA) was prepared for use in vitro studies and to infect ex vivo NHP brain tissue as previously described [12]. For in vitro human glia infection studies, Neisseria meningitidis strain MC58 was cultured in Columbia broth on an orbital shaker at 37 °C with 5% CO₂ [9]. Streptococcus pneumoniae strain CDC CS109, an isolate from a patient with meningitis, was grown from frozen stock on tryptic soy agar with 5% defibrinated sheep blood and subsequently cultured in Todd-Hewitt broth at 37 °C as previously described by our laboratory [8]. Staphylococcus aureus strain UAMS-1 was grown in lysogeny broth (LB) on an orbital shaker at 37 °C with 5% CO₂ overnight.

Nonhuman primate frontal cortex brain slice isolation and ex vivo infection

Freshly harvested frontal cortex tissues were collected at necropsy from four rhesus macaques (Macaca mulatta) that were scheduled for euthanasia due to chronic idiopathic diarrhea or had undergone trauma. Animals were euthanized in accordance with the recommendations of the American Veterinary Medical Association’s Panel on Euthanasia. The frontal cortex was sliced into 2-mm sections, and each section was placed in separate wells of 12-well plates. Each well contained 2 mL of RPMI 1640 medium (BioWhittaker, Walkersville, MO) supplemented with 10% FBS, as previously described [13]. Tissue sections were exposed to medium alone or to medium containing B. burgdorferi (1 × 10^7 bacteria/mL) and were processed for analysis at the indicated time points.

Source and propagation of human glial cell lines and primary cells

U87-MG, an immortalized human astrocytic cell line, was obtained from the ATCC (HTB-14). Cells were maintained in Eagle’s Minimum Essential Medium supplemented with 10% FBS and penicillin/streptomycin.
The human microglial cell line, hμglia, was a kind gift from Dr. Jonathan Karn (Case Western Reserve University). These cells were derived from primary human cells transformed with lentiviral vectors expressing SV40 T antigen and hTERT and have been classified as microglia due to their microglia-like morphology; migratory and phagocytic activities; presence of the microglial cell surface markers CD11b, TGFβR, and P2RY12; and characteristic microglial RNA expression profile [14]. This cell line was maintained in Dulbecco’s modified Eagle medium supplemented with 5% FBS and penicillin/streptomycin. Primary human astrocytes and microglia were purchased from ScienCell Research Laboratories (Carlsbad, CA) and were cultured in medium supplied by the vendor.

**In vitro infection of human microglia and astrocytes and exposure to bacterial components**

Cells (1.5 × 10⁵) seeded in 12-well flat-bottom tissue culture plates were infected with bacteria at the indicated multiplicities of infection (MOI) in antibiotic-free culture medium for 2 h prior to washing and addition of complete culture medium. Alternatively, human glial cells were exposed to Pam3Cys, polyinosinic-polycytidylic acid (poly I:C) sodium salt, bacterial lipopolysaccharide (LPS), and/or flagellin, ligands for TLR2, TLR3, TLR4, and TLR5, respectively. Pam3Cys was purchased from InvivoGen (San Diego, CA). Flagellin (isolated from *Salmonella typhimurium* strain 14028) was purchased from Enzolife sciences (Farmingdale, NY). LPS (isolated from *Escherichia coli*) and poly I:C were purchased from Sigma-Aldrich (St. Louis, MO). Following infection or exposure to bacterial products, cells were then cultured in the presence or absence of SP (Sigma-Aldrich) at a concentration of 5 or 10 nM. At the indicated time points, whole-cell protein isolates were collected and RNA was isolated for immunoblot analysis and semi-quantitative RT-PCR, respectively.

**RNA extraction and semi-quantitative reverse transcription PCR**

Total RNA was isolated from cultured glial cells using Trizol Reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions and quantified using a Nanodrop ND-1000 spectrophotometer. Prior to reverse transcription, RNA was treated with amplification grade DNase (Sigma-Aldrich) to remove genomic DNA. All RNA samples were diluted to the same concentration and reverse transcribed in the presence of random hexamers using 200 U of RNase H minus Moloney leukemia virus reverse transcriptase (Promega, Madison, WI) in the buffer supplied by the manufacturer. Semi-quantitative RT-PCR was performed on 5% of the reverse-transcribed cDNA product to assess the relative levels of expression of mRNA encoding NK-1R and the housekeeping gene product glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Positive and negative strand PCR primers used, respectively, were AACCCAGGGTCAAGG and ATGTAC CTATCAAGGCCCAGGC to amplify mRNA encoding total NK-1R, TCTTCTCTCCTGGCGCTACAT and AGCACCAGGGCATGTGAAAGCCCA to amplify mRNA encoding full-length NK-1R, ATCCTGGTGCC GTGGCGATC and GAGAGACTGCGCAGTCCA TAAAGA to amplify mRNA encoding preprotachykinin (PPT), and CCATCCACATCTTCCAGGACGAG and CACAGTCTCTGGTGAGCGTAT to amplify mRNA encoding GAPDH.

**Immunoblot analysis**

Homogenates from NHP frontal cortical tissue and whole-cell protein isolates from human cell cultures were subjected to immunoblot analysis as we have previously described [11, 15] using a mouse monoclonal antibody directed against human NK-1R (ThermoFisher Scientific; clone ZN003). In some experiments, nuclear protein extracts were obtained from hμglia cells as follows. Cells were suspended in a pH 7.9 lysis buffer containing 10 mM HEPES, 1.5 mM MgCl₂, 10 mM KCl, 0.5 mM DTT, 0.05% NP40, and protease inhibitor cocktail for 10 min at 4 °C. The nuclei and other fragments were pelleted by centrifugation and supernatants were retained as cytoplasmic fractions. Nuclei were lysed by exposure to pH 7.9 high salt buffer containing 5 mM HEPES, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM DTT, 26% glycerol, and 300 mM NaCl for 30 min at 4 °C. Samples were cleared of cellular debris by centrifugation, and supernatants containing the nuclear fraction were subjected to immunoblot analysis using a mouse polyclonal antibody directed against the p65 (RelA) subunit of NF-kB (Millipore, Billerica, MA). Protein bands corresponding to NK-1R or RelA were detected using a Bio-Rad ChemiDoc imaging system, and quantification was performed using ImageLab software (Bio-Rad) normalized to the expression of the housekeeping gene product β-actin. NK-1R and p65 (RelA) protein expression is presented graphically as relative levels adjusted to β-actin expression, and the immunoblots shown are representative of at least three separate experiments.

**ELISA quantification of SP levels and IL-6 production**

Levels of SP in ex vivo NHP cortical supernatants were determined using a commercially available ELISA kit according to the directions provided by the manufacturer (R&D Systems). IL-6 production by human glial cultures was assessed by specific capture ELISA using a rat anti-human IL-6 capture antibody and a biotinylated rat anti-human IL-6 detection antibody (BD Pharmingen). Bound antibody was detected by streptavidin-horseradish peroxidase
(BD Biosciences) followed by the addition of tetramethylbenzidine (TMB) substrate. H₂SO₄ was used to stop the reaction, and absorbance was measured at 450 nm. Dilution of recombinant IL-6 (BD PharMingen) was used to generate a standard curve, and the IL-6 concentration in each supernatant was determined by extrapolation of absorbances to the standard curve.

**Fluorescent immunohistochemical analysis**

H₄gliia cells (1.5 x 10⁵) were plated on acid-washed glass coverslips coated with poly-d-lysine. Cells were fixed (2% PFA), permeabilized (with 50% acetone 50% methanol solution), and blocked (5% goat serum). Cells were stained with a monoclonal mouse antibody directed against NK-1R (clone ZN003, Thermo Scientific, Rockford, IL) and a polyclonal goat antibody directed against the microglial marker Iba1 (Abcam, Cambridge, MA) prior to incubation with secondary antibodies coupled to Alexa Fluor 488 or Alexa Fluor 594. Samples were mounted with Prolong Gold containing DAPI (Invitrogen) and imaged using an Olympus 1X71 inverted microscope and an Olympus DP70 digital camera.

**Flow cytometric analysis**

U87-MG cells, primary human astrocytes, or h₄gliia cells, seeded in 12-well plates (1.5 x 10⁵) were unstimulated or exposed to bacterial products for 2 h prior to addition of an enzyme free dissociation buffer (Thermo-Fisher Scientific), washing, and blocking (5% normal goat serum). Cells were then stained with a monoclonal mouse antibody directed against NK-1R (clone ZN003, Thermo Scientific) followed by incubation with a secondary antibody coupled to either Alexa Fluor 488 or Alexa Fluor 594, prior to flow cytometric analysis using an Accuri C6 cytomter (BD Biosciences, Franklin Lakes, NJ).

**Assessment of soluble neurotoxic mediator production by infected human glia**

Primary human astrocytes were uninfected or infected with *B. burgdorferi* or *S. pneumoniae* in the absence or presence of SP (5 nM). At 24 h following infection, conditioned medium was collected and placed on HCN-1A neuronal cells. At 24 h following addition of the conditioned medium, the viability of the HCN-1A cells was assessed by trypan blue exclusion in ten microscopy fields.

**Statistical analysis**

Data are presented as the mean ± standard error of the mean (SEM). Statistical analyses were performed using Student’s two-tailed t test or a one-way analysis of variance (ANOVA) with Bonferroni’s or Tukey’s post hoc tests as appropriate using commercially available software (GraphPad Prism, GraphPad Software, La Jolla, CA). In all experiments, results were considered statistically significant when a P value of less than 0.05 was obtained.

**Results**

The full-length NK-1R isoform is constitutively and robustly expressed in the NHP brain, and SP levels are elevated following challenge with *B. burgdorferi*

We have previously demonstrated the ability of an NK-1R antagonist to ameliorate CNS inflammation associated with in vivo CNS infection in a NHP model [10]. To begin to determine whether resident CNS cells, as distinct from infiltrating leukocytes, are responsive to SP, we have determined the constitutive expression of SP and NK-1R in rhesus macaque frontal cortical tissue and assessed the level of expression of these molecules following ex vivo bacterial challenge. As shown in Fig. 1a, NHP cortical tissue showed robust constitutive expression of mRNA encoding NK-1R, and the full-length NK-1R isoform (fNK-1R) in particular, in addition to pre-pro-tachykinin (PPT) mRNA that encodes SP. While levels of fNK-1R and PPT mRNA tended to increase at 2 h following exposure to *B. burgdorferi*, this effect was not statistically significant (Fig. 1a). Importantly, the expression of NK-1R mRNA was reflected in robust levels of fNK-1R, but not the truncated NK-1R isoform (tNK-1R), in uninfected brain tissue. Such expression was not significantly altered at 2 h (Fig. 1b) or 4 h (Fig. 1c) following infection. However, *B. burgdorferi* challenge did significantly elevate SP protein expression in NHP brain tissue above the high basal levels and within 4 h (Fig. 1c).

**Human microglia constitutively and functionally express NK-1R**

To begin to determine the ability of human glial cells to respond to SP, we have assessed the expression of NK-1R by microglia, the principal myeloid immune cell of the CNS. As shown in Fig. 2a, the human microglial cell line h₄gliia constitutively expresses NK-1R as determined by immunofluorescent microscopy. NK-1R expression by h₄gliia cells was confirmed by immunoblot analysis, which showed robust constitutive levels of fNK-1R protein in the absence of detectable tNK-1R isoform expression (Fig. 2b). Such robust fNK-1R expression was not elevated further following exposure to the TLR ligands, bacterial flagellin, PAM3Cys, and LPS, or exposure to whole intact *N. meningitidis*, *S. pneumoniae*, or *B. burgdorferi*, as determined by immunoblot analysis (Fig. 2b and data not shown) and flow cytometry (data not shown). Similarly, treatment with SP, alone or in combination with bacterial ligands, failed to significantly increase fNK-1R protein expression (Fig. 2b).
Importantly, we have extended these studies to primary human microglia and we show that they also constitutively express fNK-1R but not tNK-1R (Fig. 2c). Similar to hμglia cells, LPS challenge failed to elicit a significant effect on fNK-1R expression by primary human microglia (Fig. 2c).

In order to establish the functionality of NK-1R on human microglia, we assessed the ability of SP to elicit activation of NF-kB, a master regulator of inflammatory gene transcription. Consistent with our previous results in other myeloid immune cell types including macrophages and dendritic cells [16], SP induced nuclear translocation of the NF-κB p65 subunit (RelA) in human microglial cells (Fig. 2d) confirming the functional nature of NK-1R expression by this cell type.

Human astrocytes constitutively express NK-1R, and bacterial challenge can elevate cell surface expression of this receptor by these cells

To begin to determine the ability of human astrocytes to respond to SP, we have assessed the expression of NK-1R by this cell type. As shown in Fig. 3a, the human astrocytic cell line U87-MG constitutively expresses mRNA encoding NK-1R, and these cells contain fNK-1R isoform protein in the absence of demonstrable tNK-1R expression (Fig. 3b, c). Activation of U87-MG cells with bacterial LPS elicited a transient increase in NK-1R mRNA levels at 2 h post-challenge (Fig. 3a), but this TLR4 ligand did not reproducibly elicit significant elevations in total cellular fNK-1R expression by these cells (Fig. 3b, c). Interestingly, LPS and a combination of the TLR2 and TLR5 ligands, Pam3Cys and bacterial flagellin, were able to significantly increase NK-1R expression on the surface of U87-MG cells as determined by flow cytometry (Fig. 3d).

Importantly, we have extended these studies to primary human astrocytes and we show that they also constitutively express fNK-1R (Fig. 4a–c), but not tNK-1R (data not shown), and LPS treatment can similarly increase relative NK-1R mRNA expression levels (0.32 ± 0.03 versus 0.43 ± 0.05 in untreated and LPS treated cells, respectively; \( p < 0.05, n = 5 \)) and cell surface NK-1R protein expression on these cells (Fig. 4d). In contrast to U87-MG cells, however, LPS challenge elicited modest but significant increases in the level of total cellular NK-1R protein levels in primary human astrocytes (Fig. 4a). Furthermore, exposure of these human glial cells to disparate bacterial pathogens tended to increase fNK-1R expression, and this effect was particularly marked in cells challenged with \( S. \) aureus (Fig. 4b, c). However, stimulation of primary human astrocytes with polyIC, a double-stranded RNA mimetic and TLR3 ligand, yielded equivocal results with inconsistent effects on total fNK-
1R protein expression (Fig. 4c) and cell surface NK-1R levels (Fig. 4d).

**SP augments the production of inflammatory and neurotoxic mediators by bacterially challenged human astrocytes**

To begin to determine the functional significance of NK-1R expression by human astrocytes, we have assessed the effect of SP on the production of the inflammatory mediator IL-6. As shown in Fig. 5a, SP failed to elicit significant IL-6 production by either U87-MG astrocytic cells or primary human astrocytes. However, SP significantly augmented the production of this cytokine by both U87-MG cells and primary astrocytes stimulated by bacterial LPS or a combination of bacterial flagellin and Pam3Cys (Fig. 5a and data not shown).

In addition to these TLR agonists, we have assessed whether SP can augment the immune responses of human astrocytes to disparate and clinically relevant bacterial pathogens of the CNS. As shown in Fig. 5b, SP significantly increased IL-6 secretion by primary human astrocytes in response to the Gram-negative bacteria *B. burgdorferi* and *N. meningiditis*, and the Gram-positive organisms *S. pneumoniae* and *S. aureus*. Furthermore, we determined that SP can enhance the production of soluble mediators capable of inducing neuronal cell death by human astrocytes in response to either *B. burgdorferi* or *S. pneumoniae* (Fig. 5c).

**Discussion**

Bacterial infections of the CNS constitute a group of highly damaging and often life-threatening diseases.
What makes the etiology of these diseases so perplexing is that severe CNS inflammation can be initiated by bacterial species that are generally regarded to be of low virulence [17]. While such responses may be protective, inflammation elicited by infectious agents often results in progressive CNS damage. Indeed, we have recently demonstrated that inflammation plays a key role in pathogenesis in a NHP model of acute Lyme neuroborreliosis [18]. A hallmark of developing inflammation is the synergistic interaction between cells and their products that can amplify the response. It is now widely accepted that SP, the most abundant tachykinin in the CNS, can exacerbate the inflammatory responses of both leukocytes and resident glial cells via the high affinity full-length NK-1R isoform (as reviewed in [1, 2]). Importantly, we have demonstrated that SP can augment proinflammatory mediator production by murine glia in response to bacterial challenge [9]. Consistent with this finding, we have reported that endogenous SP/NK-1R interactions are required for maximal proinflammatory cytokine expression in vivo following direct CNS administration of *N. meningitidis* or *B. burgdorferi* in mice [9]. In addition, we have shown that an NK-1R antagonist can attenuate the neuronal and glial production of inflammatory mediators including CCL2 and IL-6 in rhesus macaque frontal cortex explants and isolated DRG cells following *B. burgdorferi* challenge [19]. Furthermore, we have recently demonstrated that NK-1R antagonist treatment can attenuate aspects of the bacteria-induced inflammatory responses in CNS tissues in an in vivo NHP model of Lyme neuroborreliosis [10].

In the present study, we have confirmed the robust expression of fNK-1R in NHP cortical brain tissue, with negligible expression of the truncated low affinity isoform (as described in [20]) that has been reported to lack the ability to elicit proinflammatory responses in other cell types [21, 22]. In contrast to our studies in the NHP brain cortex at 2 weeks following in vivo *B. burgdorferi* infection [10] and a report in the rat spine following chronic stress [23], we have shown that acute ex vivo challenge with *B. burgdorferi* fails to elicit significant changes in NK-1R mRNA or protein expression above constitutive levels. However, *B. burgdorferi* infection did elicit a statistically significant elevation in SP protein levels within brain tissue, indicating that the expression of neurokinin signaling
components can be modulated in situ in response to bacterial challenge.

We have previously documented the functional expression of NK-1R by peripheral myeloid immune cell types including macrophages and dendritic cells [24, 25]. However, the expression of the SP receptor by microglia has been more contentious. Early findings indicated the absence of NK-1R expression by rat microglia based upon SP binding studies [26] while another group reported the lack of NK-1R expression by activated rat microglia following cerebral ischemia [27]. In contrast, one study reported the presence of NK-1R in human fetal microglia [28] and we have previously shown the functional expression of NK-1R by primary murine microglia [11]. In the present study, we have demonstrated the constitutive expression of full-length NK-1R protein by both a human microglial cell line and primary human microglia as determined by immunoblot analysis, immunohistochemical staining, and flow cytometry, at robust levels that could not be further elevated by exposure to bacterial ligands for TLR2, TLR4, or TLR5, either alone or in combination with SP treatment. In agreement with our results in ex vivo NHP cortical brain tissue, we were not able to detect significant levels of the truncated NK-1R isoform in human microglial cells. Furthermore, we have proved that fNK-1R is functionally expressed by human microglial cells with the demonstration that SP can elicit the activation of the critical proinflammatory transcription factor NF-κB, which is consistent with our prior studies in murine macrophages, dendritic cells, and microglia [11, 16].

In contrast to microglia, the expression of NK-1R by astrocytes has been more clearly established with the demonstration of this receptor in primary cortical mouse and rat astrocytes [29–31]. Furthermore, human brain astrocytes have been reported to express NK-1R, albeit at markedly lower levels than that seen in spinal cord cells [32]. However, it should be noted that the NK-1R isoform expressed was not defined in these studies, and at least one group has failed to detect the presence of this receptor in activated rat astrocytes following an ischemic insult [27]. Here, we show that both U87-MG human astrocytic cells and primary human cortical astrocytes express NK-1R mRNA and the full-length isoform protein as determined by immunoblot analysis and flow cytometry. Interestingly, we have found that
exposure to bacterial components that serve as ligands for TLRs can elevate NK-1R mRNA expression and cell surface protein expression by U87-MG cells. Furthermore, challenge with bacteria or their products can elevate total cellular and cell surface NK-1R protein levels by primary human astrocytes. An elevation in NK-1R expression by astrocytes following exposure to activating stimuli is consistent with the documented ability of inflammatory mediators to increase NK-1R levels in U87-MG cells and primary rat astrocytes [33] and leukocytes [24, 34].

In accord with previous studies in human spinal astrocytes and primary rat astrocytes [26, 32], SP failed to induce significant IL-6 production by either U87-MG cells or primary human astrocytes when used as the sole stimulus. However, SP significantly augmented cytokine responses by both cell types following exposure to bacterial TLR ligands. This finding is in agreement with the work of Luber-Narod and colleagues [26] in rat astrocytes, but contrasts with another early report that SP does not affect the responses of human cortical astrocytes [32]. Importantly, we have shown that SP can significantly elevate the production of IL-6 or soluble neurotoxic mediators induced by disparate Gram-negative and Gram-positive bacterial pathogens of the CNS, including B. burgdorferi, N. meningitidis, S. pneumoniae and, to a lesser extent, S. aureus.

Taken together, the robust constitutive and functional expression of the full-length NK-1R isoform by human microglia and astrocytes, and the ability of SP to
augment inflammatory signaling pathways and mediator production by these cells, support the contention that SP/NK-1R interactions play a significant role in the damaging neuroinflammation and neurological sequelae associated with bacterial infections of the CNS in human subjects. Furthermore, given the available data that SP/NK-1R interactions also augment detrimental inflammation during parasitic CNS infections and perhaps multiple sclerosis, while contributing to neuroprotection during some degenerative CNS disorders and intracellular viral/bacterial infections (as discussed in [2]), the functional expression of NK-1R by human glial cells may have broader implications. Clearly, further investigation of the ability of SP to augment CNS inflammation following infection and the benefits of targeting NK-1R in such clinical conditions is warranted.

Conclusions
Our results show that the NHP brain as well as human microglial and astrocytic cells constitutively express robust levels of the full-length isoform of the high affinity SP receptor, NK-1R. In addition, we demonstrate that the expression of NK-1R by human astrocytes can be further elevated following exposure to disparate bacterial pathogens or their components. Importantly, we have demonstrated that NK-1R is functional in both human microglia and astrocytes and show that SP can augment the inflammatory immune responses of both CNS cell types. Such an effect may underlie the previously documented ability of an NK-1R antagonist to attenuate inflammation in a NHP model of CNS infection.

Acknowledgements
Not applicable.

Funding
This work was supported by grant NS050325 to IM and MTP from the National Institutes of Health.

Availability of data and materials
The data used and/or analyzed during the current study available from the corresponding author on reasonable request.

Authors’ contributions
ARB, MBJ, VSC, MIM-S, ADY, and IDC maintained in vitro human cell cultures; carried out in vitro bacterial infections and treatments; performed semi-quantitative RT-PCR, immunoblot analyses, fluorescence microscopy, and flow cytometry; and performed data analysis. ANM and GR prepared bacterial stocks and carried out the ex vivo infections. IM and MTP conceived the study, contributed to the experimental design, and drafted the manuscript. All authors read and approved the final version of the manuscript.

Ethics approval
All protocols involving animals were approved by the Institutional Animal Care and Use Committee of Tulane National Primate Research Center.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Biological Sciences, University of North Carolina at Charlotte, 9201 University City Blvd, Charlotte, NC, 28223, USA. 2Division of Bacteriology and Parasitology, Tulane National Primate Research Center, Covington, LA, USA.

Received: 21 September 2017 Accepted: 23 November 2017 Published online: 13 December 2017

References
1. Martinez AN, Philipp MT. Substance P and antagonists of the neurokinin-1 receptor in neuroinflammation associated with infectious and neurodegenerative diseases of the central nervous system. J Neurol Neurosurg Psychiatry. 2016;87:29–36.
2. Johnson MB, Young A, Marriott I. The therapeutic potential of targeting substance P/NK-1R interactions in inflammatory CNS disorders. Front Cell Neurosci. 2016; In Press.
3. Bost KL. Tachykinin-modulated anti-viral responses. Front Biosci. 2004;9:1994–8.
4. Robinson P, Garza A, Moore J, Eckols TK, Parti S, Balaji V, Vallejo J, Twardy DJ. SP is required for the pathogenesis of EMCV infection in mice. Int J Clin Exp Med. 2009;2:76–86.
5. Kennedy PG, Rodgers J, Jennings FW, Murray M, Leeman SE, Burke JM. A SP antagonist, RP-67,580, ameliorates a mouse meningencephalitic response to Trypanosoma brucei brucei. Proc Natl Acad Sci U S A. 1997;94:4167–70.
6. Garza A, Tweardy DJ, Weinstock J, Wiswanathan B, Robinson P. Substance P signaling contributes to granuloma formation in Tammia crioceris infection, a murine model of cysticercosis. J Immunol. 2009;182:5978–86.
7. Garza A, Weinstock J, Robinson P. Absence of the substance P/substance P receptor circuitry in the substance P/precursor knockout mice or substance P receptor, neurokinin (NK)1 knockout mice leads to an inhibited cytokine response in granulomas associated with murine Taenia crassicaudata infections. J Parasitol. 2009;94:1253–6.
8. Chauhan VS, Klutz JM, Bost KL, Marriott I. Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis. J Immunol. 2011;186:7255–63.
9. Chauhan VS, Sterka DG Jr, Gray DL, Bost KL, Marriott I. Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borelzia burgdorferi. J Immunol. 2008;180:8241–9.
10. Martinez AN, Burmeister AR, Ramesh G, Doyle-Meyers L, Martin DS, Jacobs MB, Didier PJ, Philipp MT. Possible role of glial cells in the onset and progression of Lyme neuroborreliosis. J Neuroinflammation. 2009;6:23.
11. Ramesh G, Borda JT, Dufour J, Kaushal D, Ramamoorthy R, Lackner AA, Philipp MT. Interaction of the Lyme disease spirochete Borellia burgdorferi with brain parenchymal elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis. Am J Pathol. 2008;173:1415–27.
14. Garcia-Mesa Y, Jay TR, Checkley MA, Lutgge B, Dobrowolski C, Valadkhani S, Landreth GE, Kain J, Alvarez-Carbonell D. Immortalization of primary microglia: a new platform to study HIV regulation in the central nervous system. J Neuro-Oncol. 2017;23:47–66.

15. Cooley ID, Chaouhan VS, Donnezy MA, Marriott I. Astrocytes produce IL-19 in response to bacterial challenge and are sensitive to the immunosuppressive effects of this IL-10 family member. Glia. 2014;62:818–28.

16. Marriott I, Mason MJ, Ehoft A, Bost KL. Substance P activates NF-kappaB independent of elevations in intracellular calcium in murine macrophages and dendritic cells. J Neuroimmunol. 2000;102:163–71.

17. Chaouhan VS, Marriott I. Bacterial infections of the central nervous system: a critical role for resident glial cells in the initiation and progression of inflammation. Curr Immunol Rev. 2007;3:133–43.

18. Ramesh G, Didier PJ, England JD, Santana-Gould L, Doyle-Meyers LA, Martin DS, Jacobs MB, Philipp MT. Inflammation in the pathogenesis of Lyme neuroborreliosis. Am J Pathol. 2015;185:1344–60.

19. Martinez AN, Ramesh G, Jacobs MB, Philipp MT. Antagonist of the neurokinin-1 receptor curbs neuroinflammation in vivo and in vitro models of Lyme neuroborreliosis. J Neuroinflammation. 2015;12:243.

20. Douglas SD, Leeman SE. Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci. 2011;1217:83–95.

21. DeFea KA, Vaughn ZD, O'Bryan EM, Nishijima D, Déry O, Bunnett NW. The role of tachykinin receptors in glial regulation of inflammation. Curr Opin Pharmacol. 2009;9:770–7.

22. Lai JP, Lai S, Tuluc F, Tansky MF, Kilpatrick LE, Leeman SE, Douglas SD. Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci U S A. 2008;105:12605–10.

23. Bradesi S, Svensson CI, Steinauer J, Pothoulakis C, Yaksh TL, Mayer EA. Role of spinal microglia in visceral hyperalgesia and NK1R up-regulation in a rat model of chronic stress. Gastroenterology. 2009;136:1339–48.

24. Marriott I, Mason MJ, Elhofy A, Bost KL. Substance P activates NF-κB in murine astrocytes. J Neuroinflammation. 2015;12:441.

25. Marriott I, Mason MJ, Elhofy A, Bost KL. Substance P activates NF-κB in murine astrocytes. J Neuroinflammation. 2015;12:441.

26. Luber-Narod J, Kage R, Leeman SE. Substance P enhances the secretion of interleukin-6 in murine macrophages and dendritic cells. J Neuroimmunol. 2000;102:163–71.

27. Stumm R, Culmsee C, Schafer MK, Kriegstein J, Weihe E. Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. J Neurosci. 2001;21:798–811.

28. Lai JP, Zhan GX, Campbell DE, Douglas SD, Ho WZ. Detection of substance P and its receptor in human fetal microglia. Neuroscience. 2000;101(4):1137–44.

29. Torres Y, Daguet De Montety MC, el Etr M, Beaujouan JC, Glowinski J. Tachykinin receptors of the NK1 type (substance P) coupled positively to phospholipase C on cortical astrocytes from the newborn mouse in primary culture. J Neurochem. 1989;52:1913–20.

30. Palma C, Minghetti L, Astolfi M, Ambrosini E, Silberstein FC, Manzini S, Levi G, Aloisi F. Functional characterization of substance P receptors on cultured human spinal cord astrocytes: synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin E2 production. Glia. 1997;21:183–93.

31. Guo CJ, Douglas SD, Gao Z, Wolf BA, Grinspan J, Lai JP, Riedel E, Ho WZ. Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. Glia. 2004;48:259–66.